Corcept Therapeutics Inc (NASDAQ: CORT) has a higher price-to-earnings ratio of 61.78x compared to its average ratio, The 36-month beta value for CORT is at 0.18. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CORT is 93.80M, and currently, shorts hold a 13.47% of that float. The average trading volume for CORT on June 13, 2025 was 1.66M shares.
CORT) stock’s latest price update
Corcept Therapeutics Inc (NASDAQ: CORT) has seen a decline in its stock price by -0.08 in relation to its previous close of 71.24. However, the company has experienced a 3.14% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-06-05 that REDWOOD CITY, Calif.–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 annual meeting. The presentation can be found here. DAZALS is a randomi.
CORT’s Market Performance
Corcept Therapeutics Inc (CORT) has experienced a 3.14% rise in stock performance for the past week, with a 0.84% rise in the past month, and a 29.77% rise in the past quarter. The volatility ratio for the week is 1.67%, and the volatility levels for the past 30 days are at 2.56% for CORT. The simple moving average for the past 20 days is -3.47% for CORT’s stock, with a 22.13% simple moving average for the past 200 days.
Analysts’ Opinion of CORT
Many brokerage firms have already submitted their reports for CORT stocks, with Truist repeating the rating for CORT by listing it as a “Buy.” The predicted price for CORT in the upcoming period, according to Truist is $38 based on the research report published on November 06, 2023 of the previous year 2023.
SVB Securities, on the other hand, stated in their research note that they expect to see CORT reach a price target of $25. The rating they have provided for CORT stocks is “Market Perform” according to the report published on April 11th, 2023.
Piper Sandler gave a rating of “Overweight” to CORT, setting the target price at $27 in the report published on April 04th of the previous year.
CORT Trading at -1.19% from the 50-Day Moving Average
After a stumble in the market that brought CORT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.33% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CORT starting from Swisher Daniel N JR, who sale 2,200 shares at the price of $70.61 back on Jun 10 ’25. After this action, Swisher Daniel N JR now owns 0 shares of Corcept Therapeutics Inc, valued at $155,342 using the latest closing price.
Guyer William, the Chief Development Officer of Corcept Therapeutics Inc, sale 20,000 shares at $72.42 during a trade that took place back on Jun 10 ’25, which means that Guyer William is holding 5,487 shares at $1,448,475 based on the most recent closing price.
Stock Fundamentals for CORT
Current profitability levels for the company are sitting at:
- 0.16 for the present operating margin
- 0.98 for the gross margin
The net margin for Corcept Therapeutics Inc stands at 0.19. The total capital return value is set at 0.16. Equity return is now at value 21.52, with 17.64 for asset returns.
Based on Corcept Therapeutics Inc (CORT), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 26.25.
Currently, EBITDA for the company is 136.95 million with net debt to EBITDA at -0.75. When we switch over and look at the enterprise to sales, we see a ratio of 10.89. The receivables turnover for the company is 11.09for trailing twelve months and the total asset turnover is 0.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.07.
Conclusion
In conclusion, Corcept Therapeutics Inc (CORT) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
